Role of Interleukin-22 in ulcerative colitis.
IL-22
IL-22BP
STAT3
Ulcerative Colitis
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
20
10
2022
revised:
16
01
2023
accepted:
17
01
2023
pubmed:
26
1
2023
medline:
8
2
2023
entrez:
25
1
2023
Statut:
ppublish
Résumé
Ulcerative Colitis (UC) is a chronic disease, in the progression of which an immune overreaction may play an important role. IL-22 is a member of the IL-10 superfamily of cytokines and is pleiotropic in immune regulation and inflammatory responses. IL-22 can produce protective effects, promote wound healing and tissue regeneration, while it can also induce inflammatory reactions when it is chronically overexpressed. Extensive literatures reported that IL-22 played an essential role in the pathogenic development of UC. IL-22 participates in the whole disease process of UC involving signaling pathways, gene expression regulation, and intestinal flora imbalance, making IL-22 a possible candidate for the treatment of UC. In this paper, the latest knowledge to further elucidate the role of IL-22 in UC was summarized and analyzed.
Identifiants
pubmed: 36696801
pii: S0753-3322(23)00061-6
doi: 10.1016/j.biopha.2023.114273
pii:
doi:
Substances chimiques
Interleukins
0
Cytokines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
114273Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement The authors declare that there are no conflicts of interest.